Cardiogenesis patents angiogenic growth factors:
This article was originally published in Clinica
Cardiogenesis has been granted a patent covering the use of angiogenic growth factors in the treatment of severe angina resulting from coronary artery disease. The company, which has obtained exclusive licenses to the technology from its co-developers, Indiana University and Columbia University, plans to use the growth factors in conjunction with transmyocardial revascularisation (TMR) technology. Cardiogenesis recently merged with Eclipse Surgical Technologies, whose TMR system has been recommended for approval by an FDA panel (see Clinica No 832, p 15).